Pfizer's single-dose pneumococcal vaccine, Prevnar 20, is the current leader in the market for adults. But Merck expects its new shot to capture the majority of market share among adults ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Prior to COVID-19, pneumococcal vaccines were the largest vaccine market worldwide – estimated at around $8 billion – with Prevnar capturing almost $6 billion of that total in 2020 from its ...

Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

V116 (PCV21) was more cost-effective than PCV20 alone and PCV15 plus PPSV23 for the prevention of adult pneumococcal disease.

Pneumococcal vaccine polyvalent; contains a total of 575mcg polysaccharides per 0.5mL; soln for IM or SC inj; contains phenol. Pneumovax 23 induces type-specific antibodies that enhance ...

Pneumococcal Vaccine market Forecast to Surge to US$ 14.43 Billion by 2032, Achieving a Remarkable 6.4% CAGR ...

Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...